• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Landec Corporation

    6/30/23 2:46:46 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LNDC alert in real time by email
    SC 13G 1 tm2320265d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. __)*

     

     

    LIFECORE BIOMEDICAL, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.001

    (Title of Class of Securities)

     

    514766104

    (CUSIP Number)

     

    June 21, 2023

    (Date of Event Which Requires Filing of this Statement)

      

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 11 Pages 

     

     

    CUSIP No. 514766104

     

     

    1.Names of Reporting Persons

     

    Scott Miller

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)x

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
    5. SOLE VOTING POWER

    1,902,639

    6. SHARED VOTING POWER 0
    7.  SOLE DISPOSITIVE POWER

    1,902,639

    8.  SHARED DISPOSITIVE POWER 0

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,902,639

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    6.3%

     

    12.Type of Reporting Person (See Instructions)

     

    IN

     

     

    Note:

    Ownership information above is as of the end of business on June 29, 2023, the business day before the date of filing of this Schedule 13G.

     

    Page 2 of 11 Pages 

     

     

    CUSIP No. 514766104

     

     

    1.Names of Reporting Persons

     

    Greenhaven Road Investment Management, LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)x

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Delaware, USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
    5. SOLE VOTING POWER 1,902,639
    6. SHARED VOTING POWER 0
    7.  SOLE DISPOSITIVE POWER

    1,902,639

    8.  SHARED DISPOSITIVE POWER 0

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,902,639

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    6.3%

     

    12.Type of Reporting Person (See Instructions)

     

    PN

     

     

    Note:

    Ownership information above is as of the end of business on June 29, 2023, the business day before the date of filing of this Schedule 13G.

      

    Page 3 of 11 Pages 

     

     

    CUSIP No. 514766104

     

     

    1.Names of Reporting Persons

     

    MVM Funds, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)x

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    New York, USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
    5. SOLE VOTING POWER 1,902,639
    6. SHARED VOTING POWER 0
    7.  SOLE DISPOSITIVE POWER

    1,902,639

    8.  SHARED DISPOSITIVE POWER 0

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,902,639

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    6.3%

     

    12.Type of Reporting Person (See Instructions)

     

    OO

     

     

    Note:

    Ownership information above is as of the end of business on June 29, 2023, the business day before the date of filing of this Schedule 13G.

      

    Page 4 of 11 Pages 

     

     

    CUSIP No. 514766104

     

     

    1.Names of Reporting Persons

     

    Greenhaven Road Capital Fund 1, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)x

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Delaware, USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
    5. SOLE VOTING POWER

    872,741

    6. SHARED VOTING POWER 0
    7.  SOLE DISPOSITIVE POWER

    872,741

    8.  SHARED DISPOSITIVE POWER 0

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    872,741

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    2.9%

     

    12.Type of Reporting Person (See Instructions)

     

    PN

     

     

    Note:

    Ownership information above is as of the end of business on June 29, 2023, the business day before the date of filing of this Schedule 13G.

      

    Page 5 of 11 Pages 

     

     

    CUSIP No. 514766104

     

     

    1.Names of Reporting Persons

     

    Greenhaven Road Capital Fund 2, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)x

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Delaware, USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
    5. SOLE VOTING POWER

    1,029,898

    6. SHARED VOTING POWER 0
    7.  SOLE DISPOSITIVE POWER

    1,029,898

    8.  SHARED DISPOSITIVE POWER 0

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,029,898

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    3.4%

     

    12.Type of Reporting Person (See Instructions)

     

    PN

     

     

    Note:

    Ownership information above is as of the end of business on June 29, 2023, the business day before the date of filing of this Schedule 13G.

      

    Page 6 of 11 Pages 

     

     

    Item 1.

     

    (a)The name of the issuer is Lifecore Biomedical, Inc. (the “Issuer”).

     

    (b)The principal executive offices of the Issuer are located at 3515 Lyman Boulevard, Chaska, Minnesota, 55318, United States.

     

    Item 2.

     

    (a)This Schedule 13G (this “Statement” or this “Schedule 13G”) is being filed by: (1) Scott Miller; (2) Greenhaven Road Investment Management, LP, a Delaware limited partnership (the “Investment Manager”); (3) MVM Funds, LLC, a New York limited liability company (the “General Partner”); (4) Greenhaven Road Capital Fund 1, L.P., a Delaware limited partnership (“Fund 1”); and (5) Greenhaven Road Capital Fund 2, L.P., a Delaware limited partnership (“Fund 2”, and together with Fund 1, the “Funds”) (all of the foregoing, collectively, the “Reporting Persons”). Each Fund is a private investment vehicle. The Funds directly beneficially own the Common Stock (as defined below) reported in this Statement. The Investment Manager is the investment manager of the Funds. The General Partner is the general partner of the Funds and the Investment Manager. Scott Miller is the controlling person of the General Partner. Scott Miller, the Investment Manager and the General Partner may be deemed to beneficially own the Common Stock directly beneficially owned by the Funds. Each Reporting Person disclaims beneficial ownership with respect to any shares other than the shares directly beneficially owned by such Reporting Person.

     

    (b)The principal business office of the Reporting Persons is c/o Royce & Associates LLC, 8 Sound Shore Drive, Suite 190, Greenwich, CT 06830.

     

    (c)For citizenship information see Item 4 of the cover page of each Reporting Person.

     

    (d)This Statement relates to the Common Stock, par value $0.001 per share, of the Issuer (the “Common Stock”).

     

    (e)The CUSIP Number of the Common Stock is 514766104.

     

    Page 7 of 11 Pages 

     

     

    Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) ¨ An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f) ¨ An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g) ¨ A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4. Ownership.

     

    See Items 5-9 and 11 on the cover page for each Reporting Person, and Item 2, which information is given as of the end of business on June 29, 2023, the business day before the date of filing of this Schedule 13G.

     

    As of the Event Date of June 21, 2023, the beneficial ownership of the Reporting Persons was as follows:

     

      · Fund 1 directly beneficially owned 816,313 shares of Common Stock, representing 2.7% of all of the outstanding shares of Common Stock.
         
      · Fund 2 directly beneficially owned 963,306 shares of Common Stock, representing 3.2% of all of the outstanding shares of Common Stock.
         
      · Collectively, the Funds directly beneficially owned 1,779,619 shares of Common Stock, representing 5.9% of all of the outstanding shares of Common Stock.

     

    The percentages of beneficial ownership contained herein are based on 30,322,169 shares of the Issuer’s common stock outstanding as of May 26, 2023, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on June 2, 2023.

     

    Page 8 of 11 Pages 

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    (a)Not applicable.

     

    (b)Not applicable.

     

    (c)By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 9 of 11 Pages 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: June 30, 2023

     

    Scott Miller

    Greenhaven Road Investment Management, LP

    MVM Funds, LLC

    Greenhaven Road Capital Fund 1, L.P.

    Greenhaven Road Capital Fund 2, L.P.

     

     

    By:   /s/ Scott Miller  

    Scott Miller, for himself and as the Managing Member of the General Partner (for itself and on
    behalf of the Funds and the Investment Manager).

     

    Page 10 of 11 Pages 

     

     

    EXHIBIT INDEX

     

    Exhibit No. Document
       
    1 Joint Filing Agreement

     

    Page 11 of 11 Pages 

    Get the next $LNDC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNDC

    DatePrice TargetRatingAnalyst
    8/11/2022$14.00Mkt Perform → Outperform
    Barrington Research
    7/20/2022$13.00Overweight
    Stephens
    4/6/2022Outperform → Mkt Perform
    Barrington Research
    10/4/2021$15.00 → $14.00Buy
    Roth Capital
    7/30/2021$12.00 → $15.00Buy
    Roth Capital
    More analyst ratings

    $LNDC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Landec upgraded by Barrington Research with a new price target

    Barrington Research upgraded Landec from Mkt Perform to Outperform and set a new price target of $14.00

    8/11/22 9:23:39 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens initiated coverage on Landec with a new price target

    Stephens initiated coverage of Landec with a rating of Overweight and set a new price target of $13.00

    7/20/22 7:31:01 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec downgraded by Barrington Research

    Barrington Research downgraded Landec from Outperform to Mkt Perform

    4/6/22 9:22:55 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lifecore Biomedical Announces Completion of Corporate Name Change

    Common stock expected to begin trading tomorrow under new Nasdaq ticker symbol "LFCR" Lifecore global headquarters relocated to Chaska, MN Launches new investor relations website: ir.lifecore.com CHASKA, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has completed its transition to Lifecore Biomedical, including the change of its name from Landec Corporation to Lifecore Biomedical, Inc. In connection with this change, the Company's common stock is also expected to commence trading under its new Nasdaq ticker symbol "LFCR" tomorrow, N

    11/14/22 9:01:56 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical to Participate in the Stephens Annual Investment Conference on Thursday, November 17, 2022

    CHASKA, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Lifecore" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), – today announced that Jim Hall, CEO of Landec Corporation & President of Lifecore, and John Morberg, CFO will be hosting a fireside chat at the Stephens Annual Investment Conference in Nashville, TN. The Company will participate in a fireside chat on Thursday, November 17th at 8:00 AM CT. The live audio webcast will be available to all interested parties through a live audio webcast accessible on the Company's investor rel

    11/10/22 8:00:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Expects to Change Corporate Name to Lifecore Biomedical and Ticker Symbol to "LFCR" on November 14

    CHASKA, Minn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Lifecore" or the "Company") today announced that it expects to effect its previously announced corporate name change to Lifecore Biomedical, Inc. and to cause its common stock to begin trading on Nasdaq under the ticker symbol "LFCR" prior to market open on November 14, 2022. This new ticker symbol will replace the Company's current ticker symbol "LNDC," which has been used since its initial public offering in 1996. The new corporate name and ticker symbol align with the Company's ongoing strategic transformation toward its high-growth, high-value CDMO business that is focused on the development, fill and f

    11/1/22 8:00:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Schechter Joshua converted options into 9,554 shares, increasing direct ownership by 20% to 57,667 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    2/2/24 7:02:00 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calloway Nathaniel converted options into 3,981 shares, increasing direct ownership by 17% to 28,069 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    2/2/24 6:41:59 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Obus Nelson converted options into 9,554 shares, increasing direct ownership by 12% to 88,687 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    2/2/24 6:40:32 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    SEC Filings

    View All

    Landec Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

    2/16/24 4:12:45 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Landec Corporation

    SCHEDULE 13G - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    2/14/24 3:39:52 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

    1/12/24 4:51:33 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Leadership Updates

    Live Leadership Updates

    View All

    Custom Made Meals Appoints Molly Montgomery as Chief Executive Officer

    Custom Made Meals (CMM), a leading national provider of fresh, ready-to-cook (RTC) entrees, appetizers, and sides for the meat and deli departments of retail grocery and club stores, announced today that it has appointed Molly Montgomery as CEO, effective today. Ms. Montgomery has served on the CMM Board of Directors since it was acquired by Stellex Capital Management LLC (Stellex) in May of 2021 and will continue to serve on the board in her new role. Stellex is a middle-market private investment firm with strong experience in the food industry. Ms. Montgomery succeeds Dale Easdon, who has led the Company as CEO for the past three years and has worked closely with management to ensure a sm

    5/17/22 8:30:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Landec Corporation (Amendment)

    SC 13G/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    2/9/24 9:59:14 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Landec Corporation (Amendment)

    SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    1/4/24 4:00:21 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Landec Corporation (Amendment)

    SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    8/15/23 5:07:46 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Financials

    Live finance-specific insights

    View All

    Landec Corporation Reports First Quarter Fiscal Year 2023 Results

    Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year periodLifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year periodReiterates fiscal 2023 full year guidance for LifecoreCorporate rebranding to Lifecore Biomedical continues to progress SANTA MARIA, Calif. and MINNEAPOLIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), reported results for the fiscal 2023 first

    10/6/22 7:15:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Corporation Revises First Quarter 2023 Earnings Conference Call for October 6, 2022 at 8:00 a.m. ET

    SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced a change to its previously announced fiscal 2023 first quarter earnings conference call date in recognition of Yom Kippur. The Company will now report financial results before the market opens on T

    9/28/22 4:05:00 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Corporation Sets First Quarter 2023 Earnings Conference Call for October 5, 2022 at 2:00 p.m. PT

    SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it will host a conference call to discuss fiscal 2023 first quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The web

    9/21/22 8:00:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care